```json
{
"content": [
{
"type": "paragraph",
"content": "The aciclovir dispersible tablets market represents a critical segment of the antiviral therapeutics industry, offering convenient and rapid-dissolving dosage forms for treating herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections. With rising prevalence of viral infections and growing demand for patient-friendly drug delivery systems, this market remains strategically relevant for pharmaceutical innovators. The global aciclovir dispersible tablets market size was estimated at $280 million in 2025, reflecting steady industry expansion driven by pediatric applications and hospital pharmacies. This market forecast projects a CAGR of 6.2% from 2026 to 2033, underpinned by macro drivers such as surging HSV-2 cases and expanding generic drug approvals."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["North America", "Europe", "Asia-Pacific", "Rest of World"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[65, 68, 70, 72, 75, 78, 82, 86, 89, 92, 95, 98, 101], // North America
[50, 52, 54, 55, 57, 59, 61, 64, 67, 69, 71, 74, 77], // Europe
[40, 43, 46, 48, 50, 53, 57, 61, 65, 69, 73, 77, 81], // Asia-Pacific
[20, 22, 23, 24, 25, 27, 29, 31, 33, 35, 37, 39, 41] // Rest of World
]
}
},
{
"type": "paragraph",
"content": "North America remains the largest region, accounting for 42% of 2025 revenue, while Asia-Pacific is projected to register the fastest growth (7.8% CAGR), fueled by affordability of generics and rising HSV-1 cases in emerging economies. Key industry forces shaping the aciclovir dispersible tablets market forecast include technological shifts toward bioavailability optimization, regulatory dynamics streamlining generic approvals in Europe and India, and consumer behavior favoring single-dose formulations over capsules. Competitive intensity remains moderate, with players like Feroxs and Mylan dominating the landscape amid ongoing M&A activity."
}
]
}
```
